USLU, S. Et Al. 2018. The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry. EULAR2018 .

USLU, S., CAN, G., ŞENEL, S., DALKILIÇ, H. E., İNANÇ, G. N., AKAR, S., ... KOCAER, S. B.(2018). The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry . EULAR2018

USLU, SADETTİN Et Al. "The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry," EULAR2018, 2018

USLU, SADETTİN Et Al. "The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry." EULAR2018 , 2018

USLU, S. Et Al. (2018) . "The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry." EULAR2018 .

@conferencepaper{conferencepaper, author={SADETTİN USLU Et Al. }, title={The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry}, congress name={EULAR2018}, city={}, country={}, year={2018}}